Keywords
tuberculosis treatment, diabetes mellitus treatment, blood glucose, treatment outcome, glycemic control, SORT IT
This article is included in the TDR gateway.
tuberculosis treatment, diabetes mellitus treatment, blood glucose, treatment outcome, glycemic control, SORT IT
There were some minor suggestions like incorporating a reference in the Introduction and mentioning the total number of TB patients that were registered which we have included in the revised version.
See the authors' detailed response to the review by Aniwada Elias Chikee
See the authors' detailed response to the review by Madhavi Bhargava
Worldwide, tuberculosis (TB) remains a major public health problem in low- and middle-income countries. Diabetes mellitus (DM) affected 425 million people in 2017 and is projected to increase to 629 million by 20451. Globally, TB and DM are among the top ten causes of death2. Annually, of the estimated 10 million new people with active TB, one million have DM (TB-DM) and this double burden deserves attention2–4. Considering the bi-directionality of association between TB and DM5, in 2010, a collaborative framework for care and control of TB-DM was developed by World Health Organization (WHO) and the International Union Against Tuberculosis and Lung Disease (The Union)6.
Among patients with TB, DM increases risk of death, recurrence and ‘treatment failure and death’ combined when compared to not living with DM7. DM may result in early mortality and adverse outcomes among patients undergoing TB treatment8.
India has more than 25% of the global TB burden and has the second highest number of people with diabetes after China4. The prevalence of DM among adults with TB was 44% in Kerala state and 25% in Tamil Nadu state9. A recently published study from a district in Tamil Nadu (2014–15) documented a prevalence of 14%10. In 2012, a feasibility study was conducted in India’s revised national TB control programme (RNTCP) settings for bidirectional screening for TB-DM11, based on which in the same year a policy decision was taken to screen all TB patients for DM. The programme also recommends recording of fasting blood glucose (FBG) values at baseline, the end of intensive phase (IP) and the end of continuation phase (CP) of TB treatment12,13.
Considering that systematic monitoring and recording of glycemic status among patients with TB-DM has been initiated in some districts of Tamil Nadu, this presents a unique opportunity for understanding the same in programme setting. Recording of FBG at baseline and during TB treatment will provide reliable information not only for management of patient’s glycemic status but also to assess the effect of optimal glycemic control on TB treatment outcomes among patients with TB-DM, the evidence for which is limited14.
Therefore, this study was conducted among patients with TB-DM registered for TB treatment in 2016 under the programme in select districts of Tamil Nadu, India. The specific objectives were to determine i) the availability of FBG at various phases of TB treatment as per programme recommendations; and ii) the number (proportion) without optimal glycemic control at baseline and during TB treatment.
This was a descriptive study involving record review of routinely collected programme data.
General setting. Tamil Nadu is a state in south India along the eastern coast with predominantly plain terrain. (Figure 1) Tamil Nadu has a population of 72 million and is made up of 32 administrative districts. The literacy rate is 80%15.
Study districts. The study was conducted in programme setting in Tiruvallur, Madurai and Tiruppur districts of Tamil Nadu. Tiruvallur is a suburb of Chennai (the capital of Tamil Nadu). Tiruppur and Madurai districts are located in west and south Tamil Nadu, respectively (Figure 1).
Under RNTCP in 2016, each district had one district TB centre, sub-district administrative units called as TB units (Tiruvallur-14, Madurai-21, Tiruppur-16) and designated microscopy centers (Tiruvallur-31, Madurai-35, Tiruppur-20). Diagnosed patients were registered for treatment and entered into the treatment register at the TB unit. Patients received domiciliary directly observed treatment (thrice weekly) which was according to the then national treatment guidelines. TB treatment outcomes (end IP and end treatment outcomes) were recorded in line with WHO recommendations and have been summarized in Box 116.
End of TB treatment – minimum 6 month follow up and maximum up to 31 May 2017
- death, treatment failed, loss to follow up, not evaluated (unfavourable treatment outcome)
- treatment completed, cure (favourable treatment outcome)
Cured: ’Cured’ defined as “A pulmonary TB patient with bacteriologically-confirmed TB at the beginning of treatment who was smear- or culture-negative in last month of treatment and on at least one previous occasion”;
Treatment completion: ’Treatment completed’ defined as “A TB patient who completed treatment without evidence of failure, but with no record to show that sputum smear or culture results in the last month of treatment and on at least one previous occasion were negative, either because tests were not done or because results are unavailable”;
Loss to follow-up: ’Loss to follow-up’ defined as “A TB patient who did not start treatment or whose treatment was interrupted for two consecutive months or more”;
Treatment failed: ’Treatment failed’ defined as “A TB patient whose sputum smear or culture is positive at month five or later during treatment”;
Died: ’Died’ defined as “A TB patient who dies for any reason before starting or during the course of treatment”;
Not evaluated: ’Not evaluated’ defined as “A TB patient for whom no treatment outcome is assigned. This includes cases “transferred out” to another treatment unit as well as cases for whom the treatment outcome is unknown to the reporting unit”.
End of Intensive phase
- Death. Loss to follow up, extension of IP and non-conversion at 3 / 4 months (Unfavourable)
- Microbiological conversion (Favourable)
Sputum conversion: those who are sputum negative latest by 3 months for new patients and latest by 4 months for retreatment patients
Sputum non-conversion: those who are sputum positive at 3 months for new patients and at 4 months for retreatment patients
TB-DM collaboration. One of the activities under TB-DM collaborative framework consists of screening for DM among all patients with TB (initiated in study districts in 2015) and monitoring glycemic control during TB treatment among all patients with TB-DM (initiated in 2016). Patients with TB are first screened with random blood glucose (RBG) at designated microscopy centers; those with RBG≥140 mg/dl (7.8 mmol/l) are assessed using FBG. Those with FBG≥126 mg/dl (7 mmol/l) are referred to higher centers for clinical confirmation of DM and initiation of treatment. This is followed by treatment continuation at the peripheral health centers12.
Patients with TB-DM undergo FBG at the end of IP and at the end of CP and the same are entered in the TB treatment card and register12. There is no specific modification in either DM or TB treatment because of the co-morbidity. TB and DM management is done free of cost.
The study population included all patients with TB-DM comorbidity (age ≥15 years) registered under RNTCP between January and September 2016 in Tiruvallur, between January and June 2016 in Madurai and between April and June 2016 in Tiruppur. Patients with multi-drug-resistant TB were excluded from the study.
A review of records was conducted between October 2016 and May 2017. Data were collected from TB treatment registers and patient treatment cards using a paper-based data collection form. Each patient was given a unique identifier derived from district code, tuberculosis unit name and TB registration number.
Baseline socio-demographic characteristics, baseline clinical characteristics and treatment outcomes (end IP and end treatment) were collected. In addition, blood glucose values at baseline, at the end of IP and at the end of CP along with the type of test (FBG or RBG) were collected.
Data collected were double-entered, validated and analysed using EpiData (version 3.1 for entry and version 2.2.2.183 for analysis; EpiData Association, Odense, Denmark). Frequency and proportions were used to summarize the key analytic outputs.
The cut off for optimal glycemic control was <130 mg/dl (7.2 mmol/l) for FBG and <180 mg/dl (10 mmol/l) for RBG. The cut off (to define optimal control) for post-prandial blood glucose was used for RBG17. If both FBG and RBG were known, FBG was used for determining optimal glycemic control. ‘Glycemic control during TB treatment’ was classified as ‘optimal’ (if both baseline and end IP values were optimal), ‘not optimal’ (if baseline and/or end IP were not optimal) or ‘missing’ (if both baseline and end IP values were missing; or if one of the two values were missing and the other was optimal). TB treatment outcomes (both end IP and end treatment) were reclassified as favourable or unfavourable (Box 1).
Ethical approval was obtained from the Institutional Ethics Committee of the Resource Group for Education and Advocacy for Community Health, Chennai, Tamil Nadu, India, and the Ethics Advisory Group of the International Union Against Tuberculosis and Lung Disease, Paris, France. As the study involved review of existing patient records, a waiver for informed consent was sought and approved by the respective ethics committees. We conducted the study after receiving approval from the State Tuberculosis Officer.
Of 5115 patients registered with TB, there were 438 (8.6%) patients with TB-DM: 270 from Tiruvallur, 114 from Madurai and 54 from Tiruppur. The baseline socio-demographic and clinical characteristics of patients with TB have been summarized in Table 1. Extracted values for each participant are available as Underlying data18.
Blood glucose records (either FBG or RBG) were available for 94% at baseline, 79% at the end of IP and 59% at the end of CP. However, FBG at baseline, at the end of IP and at the end of CP were each available for less than 20% patients. RBG at baseline, at the end of IP and at the end of CP were each available for 76%, 60% and 43%, respectively (Table 2).
Optimal Control* N (%)** | Not optimal control N (%)** | Missing N (%)** | |
---|---|---|---|
Based on RBG | |||
At baseline | 59 (14) | 270 (62) | 109 (25) |
At end intensive phase | 98 (22) | 168 (38) | 172 (39) |
At end continuation phase | 82 (19) | 104 (24) | 252 (58) |
Based on FBG | |||
At baseline | 37 (8) | 48 (11) | 353 (81) |
At end intensive phase | 43 (10) | 39 (9) | 356 (81) |
At end continuation phase | 51 (12) | 22 (5) | 365 (83) |
Based on PPBG | |||
At baseline | 22 (5) | 63 (14) | 353 (81) |
At end intensive phase | 27 (6) | 53 (12) | 358 (82) |
At end continuation phase | 33 (8) | 40 (9) | 365 (83) |
Based on RBG or FBG^ | |||
Baseline | 96 (22) | 316 (72) | 26 (6) |
At end intensive phase | 141 (32) | 207 (47) | 90 (21) |
At end continuation phase | 133 (30) | 126 (29) | 179 (41) |
During TB treatment# | 63 (14) | 337 (77) | 38 (9) |
RNTCP, Revised National Tuberculosis Control Programme; RBG, random blood glucose; FBG, fasting blood glucose; PPBG, 2-hour post prandial blood glucose. *RBG, FBG, PPBG cut off of 130, 180 and 180 mg/dl respectively; **row percentage; ^FBG preferred over RBG if available; #‘optimal’ (both baseline and IP status optimal), ‘not optimal’ (any one status was not optimal) and missing (both were missing).
Glycemic control status was known for 94% (412/438) patients at baseline and for 91% (400/438) during TB treatment. Among those with known glycemic status, glycemic control was not optimal in 77% (316/412) patients at baseline and in 84% (337/400) during TB treatment.
In total, 46 patients (10%) had unfavourable end IP outcomes (5% sputum non-conversion, 2% death and 3% not evaluated); 21 patients (5%) had unfavourable end treatment outcomes (1% treatment failed, 3% deaths and 1% not evaluated).
We decided against assessing factors associated with glycemic control during TB treatment and association between glycemic control and TB treatment outcomes because glycemic control assessment, if any, was based mostly on RBG values, which are unreliable.
This operational research had two key findings. First, though blood glucose values were available during baseline and end IP in four-fifths of patients, most of these values were RBG. FBG was not consistently recorded during baseline, the end of IP and the end of CP (as per programme guidelines). Routinely, patients with TB screened at peripheral health centers using RBG and/or FBG are referred to higher institutions for clinical confirmation. Even if FBG is not measured at peripheral health center at baseline, it ought surely to be measured at the higher center. This FBG at baseline, which is at least expected for all newly diagnosed DM patients at the time of registration for TB treatment, is not reflected in the RNTCP records (only 19% have baseline FBG records). There is one possible reason for this. During data collection, we found that RBG was predominantly measured and recorded as it was the blood glucose test mentioned in the TB treatment card. In a study conducted in 18 randomly selected districts of India, poor documentation of DM status among TB patients from marginalised and vulnerable populations (2016–2017) was observed19.
Second, a large number of patients did not have optimal glycemic control at baseline and during TB treatment. Though these findings are mostly based on RBG that was available, our figures are comparable with findings from another study by Mahishale et al.20 at a private tertiary care facility in Karnataka, India, where poor glycemic control (HbA1C ≥7%) at baseline was seen in 67% (423/630) patients. Another study in India from programme setting by Nandakumar et al.21 identified 667 patients with TB-DM, 36% cases had known (minimum three blood glucose values available, at least one month apart) diabetic control status during the treatment, of which 43% cases were under glycemic control. However, the cut offs (FBG <100 mg/dl and RBG <140) used were lower than the ones used by us. The cut-off values used by us were as per international recommendations22.
This study has two key policy implications. First and foremost, systematic recording of FBG should be improved. Though HbA1c has been described as the gold standard for glycemic control, as per programme recommendations FBG should be systematically recorded in the treatment cards (considering the lack of access to HbA1c in programme settings)12,13. One potential solution for this is an incremental administrative change that may easily be incorporated. Newly printed treatment cards replacing RBG with FBG would suffice.
Second, poor glycemic control indicates that there is an urgent need to improve glycemic management among patients with DM. Tamil Nadu has a well-established primary health care system where DM treatment is provided through the peripheral health centres. Existing DM treatment guidelines, if any, should be reviewed to ensure that management is as per international recommendations17,23–26. Poor glycemic control has been reported among patients with DM in Asian countries27,28. Programmatic interventions to maintain a line list of registered patients with DM (in line with TB and HIV programmes) may be considered. This will ensure proper tracking of DM treatment outcomes29. Integrating care of communicable and non-communicable diseases (such as TB and DM, respectively) has also been recommended in literature30.
To our knowledge, this is the first study which has systematically reported the recording of blood glucose values among patients with TB-DM at various phases of TB treatment in programmatic setting in India. We found two similar studies; however, they did not review glycemic control measurement as per the recent 2016 programme recommendations20,21. This study was conducted in the programme setting; therefore, findings are reflective of reality on the ground. Double data entry and validation minimized data entry errors.
There was a major limitation. As RBG was the most frequent type of blood glucose value recorded, glycemic control reported should be interpreted with caution. For the same reason analysis of the association between glycemic control and TB treatment outcome would have been meaningless and hence, was not performed. RBG is a screening test for diabetes and is not recommended for monitoring glycemic control22.
In this operational research, involving patients with TB-DM in programmatic setting from South India, we found FBG was not consistently recorded as per programme guidelines (at baseline, the end of intensive phase and the end of continuation phase of TB treatment). The glycemic control status (mostly based on random blood glucose instead of fasting blood glucose or HbA1c) was not reliable to perform a meaningful analysis of its effect on TB treatment outcomes. This calls for an urgent review of the TB-DM collaborative services to improve the recording of glycemic control during TB treatment.
Figshare: Data set for Gurukartick study 2016. https://doi.org/10.6084/m9.figshare.990218018.
File ‘Dataset_v2’ contains all de-identified variables extracted for this study, alongside a codebook explaining all abbreviations and values.
Data are available under the terms of the Creative Commons Zero “No rights reserved” data waiver (CC0 1.0 Public domain dedication).
Principal Investigator: JG; Mentors: HDS, AGJ, OPA; Senior authors: RA, NK; Conception and design: JG, HDS, AGJ; Data collection: JG, LM, MMS, DD, GM; Development of data capture tool: JG, OPA, HDS; Data analysis and interpretation: JG, HDS, AGJ, OPA, RA, NK; Preparation of first draft; JG, HDS; Critical review and approval of final draft: all authors.
We would like to acknowledge Mr. Rajeswaran, Mrs. Sheela Augusteen, Mr.Dilesh and our urban co-ordinators Ms. Rubini Raghunathan, Mr. Srinivasan, Mr. John Paul Jeeva, Mr. Pandiaraj, and Mr. Saravanan (MMCF NGO) who helped us in data collection. We do thank the Senior Treatment Supervisors and District Program Managers for their co-operation and support.
Disclaimer: The contents of this paper do not necessarily reflect the views of the Government or Non-Governmental Organizations or The Union
Views | Downloads | |
---|---|---|
F1000Research | - | - |
PubMed Central
Data from PMC are received and updated monthly.
|
- | - |
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Yes
Competing Interests: No competing interests were disclosed.
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Yes
Competing Interests: No competing interests were disclosed.
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | ||
---|---|---|
1 | 2 | |
Version 2 (revision) 11 Jun 20 |
||
Version 1 07 Oct 19 |
read | read |
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Already registered? Sign in
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
Comments on this article Comments (0)